Free fatty acids inhibit growth hormone/signal transducer and activator of transcription-5 signaling in human muscle: a potential feedback mechanism.

What Was Tested

Researchers studied Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in this randomized controlled trial publication.

Based on preliminary results, the researchers intended to test whether FFAs exert a negative feedback inhibition of STAT5 phosphorylation in skeletal muscle.

Who Took Part

By PubMed's age tags, the people studied were young adults and adults, men only.

Eight healthy young men were investigated for 8 h on four occasions at four different FFA levels in a single blind, randomized manner.

How the Study Was Run

The design is described as randomized and single-blind.

Because people in this Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Only one side, usually the participants, was kept unaware of whether Exogenous HGH, sermorelin & older GHRPs (why they're passed over) was given.

Acipimox was used to suppress FFA levels and Intralipid was infused to obtain appropriate FFA concentrations.

Somatostatin was infused to control GH levels and GH, insulin, and glucagon were replaced.

Muscle biopsies were taken after 8 h and compared with a fifth biopsy taken under normal basal conditions.

The study was conducted at a university clinical research unit.

What Was Measured

Topics PubMed links to this paper include Fatty Acids, Nonesterified, Feedback, Physiological, Human Growth Hormone, Infusion Pumps, Muscle, Skeletal, Phosphorylation and Protein Kinases.

What This Means in Plain Language

The paper is a randomized and single-blind study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

The abstract goes on to report its results in about 4 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2009 (The Journal of clinical endocrinology and metabolism), a journal based in United States.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.